A thymic factor previously shown to stimulate the DNA synthesis of immature thymocytes was found to recruit G1 cells synchronously into S phase within 1.5–2 h. The S + G2 + M duration of the cultured thymocytes was not affected. In the absence of the thymic factor, the responding thymocytes seemed to be blocked in G1 at a putative restriction point 1.5 h prior to S phase. When the addition of the thymic factor to cultured cells was delayed, the responsiveness rapidly declined, indicating that target cells were transferred into an unresponsive state. A stimulating effect of the DNA synthesis of cultured thymocytes was obtained also after a transient exposure to the thymic factor for 2–3 h. The stimulating activity was completely absorbed from the medium by incubation with thymocytes at both 4 and 37 °C, but not by lymph node lymphocytes which are unresponsive to the thymic factor. Our interpretation of the results is that the thymic factor acts on thymocytes in G1, triggering the responsive cells via membrane receptors to proceed from G1 into S phase. The thymic factor is proposed to be a progression factor for the rapidly cycling immature thymocytes and to be involved in the regulation of the intense thymic growth in vivo.

This content is only available via PDF.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.